All In Biotech

Drug Trial Radar · NCT05735496

Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers

A Phase I Study of TQB2102 Injection in Patients With Advanced Cancers

Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

219

Actual

Start

Mar 9, 2023

Primary completion

Jul 21, 2025

Study completion Jul 2027

Sponsor

Sponsor type
Industry
First posted
Feb 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a phase I study to evaluate the safety, tolerability and effectiveness of TQB102 injection in subjects with advanced malignancies.

Conditions

  • Advanced Cancer

Interventions

  • TQB2102 injectionDrug

    TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against HER2, a enzyme-cleavable linker, and a topoisomerase I inhibitor payload.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (DLT)Time frame: During the first treatment cycle (21 days).
  2. Maximum tolerated dose (MTD)Time frame: During the first treatment cycle (21 days).
  3. The occurrence rate of all adverse events (AEs)Time frame: From date of the first dose until 28 days after last dose or new anti-tumor treatment, whichever came first.
  4. Dose escalation: recommended phase 2 dose (RP2D)Time frame: Up to 2 years

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian Cancer Hospital.

    Fuzhou, Fujian, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Harbin Medical University Cancer Hospital, Harbin, China

    Harbin, Heilongjiang, China

  • The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China

  • Fudan University shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Shanghai, Shanghai Municipality, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Mianyang Central Hospital

    Mianyang, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.